Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study
Background: Sertraline is commonly prescribed to children for the treatment of anxiety and major depressive disorder and is metabolized in part by CYP2C19. While dosing recommendations based on CYP2C19 genotype exist, there is sparse data in children on the relationship between sertraline concentra...
Main Authors: | Katelyn France, David Ammend, Jacob Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2022-12-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/5035 |
Similar Items
-
Effect of citalopram and sertraline on the expression of miRNA- 124, 132, and 16 and their protein targets in patients with depression
by: Mahnaz Ahmadimanesh, et al.
Published: (2023-07-01) -
Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults
by: Nathan John Hanan, et al.
Published: (2019-02-01) -
Impact of Updating Pharmacogenetic Results: Lessons Learned from the PREDICT Program
by: Michelle Liu, et al.
Published: (2021-10-01) -
Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients
by: Zi Zhang, et al.
Published: (2024-02-01) -
Lower sertraline plasma concentration in patients co‐medicated with clozapine—Implications for pharmacological augmentation strategies in schizophrenia
by: Arnim Johannes Gaebler, et al.
Published: (2023-04-01)